Notice of Extension for RFA-TR-25-002 "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)"
Notice Number:
NOT-TR-26-009
Key Dates
Release Date:
June 5, 2026
Related Announcements
- December 06, 2024 - Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed). See NOFO RFA-TR-25-002.
Issued by
National Center for Advancing Translational Sciences (NCATS)
Purpose
The purpose of this Notice is to inform applicants that effective immediately the National Center for Advancing Translational Sciences (NCATS) is extending RFA-TR-25-002 "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" by one Council round.
The following text in bold and italics has been updated to reflect the extension:
Part 1. Overview Information
Key Dates
| Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| June 02, 2026 | June 02, 2026 | Not Applicable | October 2026 | January 2027 | April 2027 |
| June 02, 2027 | June 02, 2027 | Not Applicable | October 2027 | January 2028 | April 2028 |
Expiration Date: June 03, 2027
All other aspects of the NOFO remain the same.
Inquiries
Please direct all inquiries to:
Office of Drug Development Partnership Programs
Email: [email protected]
Department of Health
and Human Services (HHS)
and Human Services (HHS)
